Human papillomavirus-related penile squamous cell carcinoma

Summary

Human papillomavirus-related penile squamous cell carcinoma (MONDO:0020656) is a cancer and 5 clinical trials. Top therapeutic interventions include avelumab. A subtype of squamous cell carcinoma of penis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	human papillomavirus-related penile squamous cell carcinoma
Mondo ID	MONDO:0020656
NCIT	C27682
UMLS	C1334056
MedGen	235178
GARD	0025200
Anatomy (UBERON)	UBERON:0000989
Is cancer (heuristic)	yes

Also known as: HPV-related penile squamous cell carcinoma · human papilloma virus related penile squamous cell carcinoma · human papilloma virus-related penile squamous cell carcinoma · human papillomavirus-related penile squamous cell carcinoma

Disease family

This is a subtype of squamous cell carcinoma of penis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › squamous cell carcinoma of penis › human papillomavirus-related penile squamous cell carcinoma

Related subtypes (4): sarcomatoid penile squamous cell carcinoma, penis mixed squamous cell carcinoma, papillary carcinoma of the penis, penis carcinoma in situ

Subtypes (2): basaloid carcinoma of the penis, warty carcinoma of the penis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	3
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03260023	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
NCT05639972	PHASE1/PHASE2	RECRUITING	E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
NCT05686226	PHASE2	RECRUITING	E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT06505551	PHASE1/PHASE2	NOT_YET_RECRUITING	Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
NCT05973487	PHASE1	ACTIVE_NOT_RECRUITING	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AVELUMAB	4	1